Wellgistics Health, Inc. (WGRX) Explores $105M Acquisition of Neuritek to Expand Healthcare Platform

We recently compiled a list of the 12 Penny Stocks with Insider Buying in 2026.  Wellgistics Health, Inc. is one of the stocks with Insider buying in 2026.

TheFly reported on March 23 that WGRX announced it had signed a non-binding, non-exclusive Letter of Intent to explore a potential all-stock acquisition of Neuritek Therapeutics, a company specializing in neuroscience research. The proposed $105 million deal, if completed, aims to expand WGRX’ existing healthcare platform by integrating research capabilities alongside its technology-driven pharmacy distribution and services operations.

By combining prescription fulfillment, wholesale distribution, and AI-enabled patient access, Wellgistics Health, Inc. (NASDAQ:WGRX) seeks to better connect manufacturers, providers, and independent pharmacies nationwide. The acquisition could improve coordination between drug development and commercialization, enhance pipeline visibility, support new revenue opportunities, and create a more integrated platform to strengthen long-term shareholder value.

In a recent corporate move, on March 19, WGRX converted roughly $2 million of accrued compensation into common stock at $0.20 per share, resulting in the issuance of about 10 million shares.

Alongside this, the company granted 10 million warrants exercisable at $0.01 per share with a five-year term. The conversion, approved by independent board members, reflects management’s confidence in the company’s strategy and aligns leadership incentives with long-term shareholder value. Newly issued shares are subject to a six-month lock-up, with customary exceptions. This transaction is designed to reinforce commitment to the company’s growth while supporting alignment between executives, directors, and shareholders.

Wellgistics Health, Inc. (NASDAQ:WGRX) is a Tampa‑based healthcare and pharmaceutical logistics company offering wholesale distribution, prescription fulfillment, technology‑enabled pharmacy services, and clinical support to independent pharmacies and manufacturers.

While we acknowledge the potential of WGRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.